Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

CAPS Rating: 3 out of 5

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

Results 1 - 20 of 167 : 1 2 3 4 5 6 7 8 9 Next »

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 2/19/2014 5:52:44 AM : Outperform Start Price: $6.93 ARNA Score: -40.40

Prediction TOS

Recs

0
Member Avatar smooreco (< 20) Submitted: 1/21/2014 11:56:33 AM : Outperform Start Price: $7.11 ARNA Score: -42.26

Obesity drugs have yet to tap the market. I think it will be a huge market.

Recs

0
Member Avatar camarodan64 (98.54) Submitted: 1/15/2014 3:20:20 PM : Outperform Start Price: $6.34 ARNA Score: -34.25

well sales are starting to go parabolic for arena now. Arna could be plus $10 a share soon, 29% shares are short....run up
could put it to $15 or $20 this year

Recs

0
Member Avatar rangerbob42 (< 20) Submitted: 11/24/2013 11:58:55 PM : Outperform Start Price: $5.85 ARNA Score: -30.04

new partner in the works to help get this product out with 60 million and 400 sale force within two months.

Recs

0
Member Avatar rknapton (< 20) Submitted: 7/23/2013 8:22:55 PM : Underperform Start Price: $6.95 ARNA Score: +49.20

Short. Biopharma. Revs up slightly, but so much r+d and expenses its ridiculous. Consistent shareholder dilution by issuing more and more stock. Lots of insider selling.

Recs

0
Member Avatar Flygal5 (98.94) Submitted: 6/11/2013 11:38:27 PM : Outperform Start Price: $8.99 ARNA Score: -67.61

New obesity drug

Recs

0
Member Avatar Jm262 (40.08) Submitted: 5/9/2013 9:13:03 PM : Outperform Start Price: $8.23 ARNA Score: -66.68

I'm a little surprised that ARNA has had so much of a pullback after it rallied from the DEA decision. I was really expecting it to at least have a few good days before a correction. I'm still long this position and i'm sure the sales will do fine once it hits the market.

Recs

0
Member Avatar mikemicmac (< 20) Submitted: 5/4/2013 11:23:44 AM : Outperform Start Price: $7.62 ARNA Score: -60.67

It seems like Americans are always looking for that pill that takes care of their needs especially when it comes to dieting. The market here is beyond vast and the drug has been approved! If this diet aid is marketed well I believe we are looking at huge amounts of sales. Go Belviq!!

Recs

0
Member Avatar TheStockDoctor (< 20) Submitted: 3/3/2013 9:31:30 PM : Outperform Start Price: $8.20 ARNA Score: -72.45

ARNA stands poised on the edge of a major blockbuster diet drug that has the potential to hit the coveted billion dollar annual status.

Recs

1
Member Avatar rteberg (< 20) Submitted: 1/22/2013 7:22:21 PM : Outperform Start Price: $8.82 ARNA Score: -78.52

Weight loss drug will have great acceptance in the market

Recs

2
Member Avatar MRJOSEPHD (< 20) Submitted: 1/10/2013 11:24:07 AM : Outperform Start Price: $9.62 ARNA Score: -85.32

1. US Launch of Anti-Obesity Drug
2. EU Approval
4. Lucrative Partnership Royalties
5. New Partnerships

Recs

3
Member Avatar Odilious (< 20) Submitted: 1/7/2013 12:42:45 PM : Outperform Start Price: $8.99 ARNA Score: -82.64

I'm new to the investing world, but this company is soon to release the first FDA approved weight loss drug in over a decade. Also, the DEA has said that it's non addictive and given the green light. 68% of Americans are overweight or obese, so I can't see how a company producing a drug that will be used by roughly 200 million people will go wrong.

Recs

0
Member Avatar DS31 (33.07) Submitted: 1/3/2013 3:01:26 PM : Outperform Start Price: $8.92 ARNA Score: -81.98

Stock price will be based solely on sales expectations and revenue RESULTS. Everything else is just noise.

Recs

1
Member Avatar rickoshay14 (< 20) Submitted: 12/30/2012 12:51:05 PM : Outperform Start Price: $8.85 ARNA Score: -87.44

I find that Arena has done a great job in setting up Belviq to achieve it's market potential, which addresses a global problem and is huge, but Arena will do well because it continues to Partner and develop a larger pipeline. In addition, once Belviq has past many approval hurdles, there are many other opportunities for Belviq to address other large health issues. I believe that once Arena's Partners begin marketing, there will be no doubt that Arena will outperform for many years to come, provided that they are not bought out

Recs

1
Member Avatar BioPharmacist (< 20) Submitted: 12/12/2012 1:50:40 AM : Outperform Start Price: $9.22 ARNA Score: -85.31

Euro approval and strong US sales this this sweet stick higher on 2013. Look for 15 by summer with maybe $20 by end of 2013

Recs

0
Member Avatar earlyseller (< 20) Submitted: 12/10/2012 8:40:00 PM : Underperform Start Price: $8.77 ARNA Score: +83.70

Based on my unreliable psychic powers of guessing about medical field.

Recs

0
Member Avatar clstanely7878 (< 20) Submitted: 12/5/2012 8:30:39 AM : Outperform Start Price: $8.65 ARNA Score: -84.61

Yes

Recs

1
Member Avatar TMFBiologyFool (97.16) Submitted: 11/28/2012 3:56:55 PM : Underperform Start Price: $9.25 ARNA Score: +87.86

Short the launch.

Recs

0
Member Avatar hbarker (< 20) Submitted: 11/11/2012 8:25:40 PM : Outperform Start Price: $6.50 ARNA Score: -48.89

current drug in trial looks like it will be approved

Recs

0
Member Avatar safaritrekker (62.38) Submitted: 10/30/2012 11:47:21 AM : Outperform Start Price: $8.46 ARNA Score: -82.99

OUTPERFOM MARKET --RISK THAT WILL NOT BE APPROVED IN EUROPE AND LESS EFFECTIVE THAN VVUS PRODUCT ARE OVERBLOWN.

Featured Broker Partners


Advertisement